Objective-Antiatherosclerotic effects of tumor necrosis factor-α (TNF-α) blockade in patients with systemic inflammatory states are not conclusively demonstrated, which suggests that effects depend on the cause of inflammation. Macrophage LRP1 (low-density lipoprotein receptor-related protein 1) and apoE contribute to inflammation through different pathways. We studied the antiatherosclerosis effects of TNF-α blockade in hyperlipidemic mice lacking either LRP1 (MΦLRP1 −/− ) or apoE from macrophages. Approach and Results-Lethally irradiated low-density lipoprotein receptor (LDLR) −/− mice were reconstituted with bone marrow from either wild-type, MΦLRP1 −/− , apoE −/− or apoE −/− /MΦLRP1 −/− (DKO) mice, and then treated with the TNFα inhibitor adalimumab while fed a Western-type diet. Adalimumab reduced plasma TNF-α concentration, suppressed blood ly6C hi monocyte levels and their migration into the lesion, and reduced lesion cellularity and inflammation in both wild-type→LDLR −/− and apoE −/− →LDLR −/− mice. Overall, adalimumab reduced lesion burden by 52% to 57% in these mice. Adalimumab reduced TNF-α and blood ly6C hi monocyte levels in MΦLRP1 −/− →LDLR −/− and DKO→LDLR −/− mice, but it did not suppress ly6C hi monocyte migration into the lesion or atherosclerosis progression. Conclusions-Our results show that TNF-α blockade exerts antiatherosclerotic effects that are dependent on the presence of macrophage LRP1.
I nflammation plays a fundamental role in all stages of atherosclerosis, 1 from the early lesion to the complex plaque. 2 Hyperlipidemia induces inflammation and is atherogenic. In addition, systemic inflammatory states, such as rheumatoid arthritis, confer predisposition to atherosclerosis. 2 A meta-analysis of observational studies shows that patients with rheumatoid arthritis have increased cardiovascular mortality compared with the general population. 3 ApoE induces an anti-inflammatory phenotype in mice by suppressing macrophage migration and chemokine secretion. 4 Deficiency of ApoE in macrophages causes systemic inflammation with monocytosis and promotes atherosclerosis. [5] [6] [7] Local inflammation in the artery wall recruits monocyte/macrophages and drives atherosclerosis. 1, 8 Cholesterol loading of macrophages in the atherosclerotic plaque activates macrophage cytokine secretion 9 and causes endoplasmic reticulum stress and apoptosis of lesion foam cells. 10 These apoptotic macrophages are then cleared by active phagocytes in a process called efferocytosis. 1, 8 Efficient efferocytosis prevents the release of inflammatory factors from dead cells and limits inflammation. 11 In advanced atherosclerotic lesions with increased macrophage apoptosis, efferocytosis becomes inefficient. This inefficient efferocytosis increases cytokine secretion, amplifies inflammatory responses, eventually leading to plaque progression, disruption, and atherothrombosis. 8 Macrophage LRP1 (low-density lipoprotein receptorrelated protein 1) is a membrane receptor linked to inflammatory signaling and efferocytosis. 12 LRP1 mediates the induction of focal adhesion disassembly 13 and is involved in triggering engulfment during phagocytosis. 14 LRP1 acts in conjunction with calreticulin serving as a recognition receptor to mediate apoptotic cell uptake. [15] [16] [17] Lack of LRP1 impairs macrophage phagocytic function and impairs efferocytosis both in vivo and in vitro. [18] [19] [20] Macrophage-specific deficiency of LRP1 (MΦLRP1 −/− ) increases atherosclerosis in hyperlipidemic mice, an effect associated with defective efferocytosis and increased inflammation. [20] [21] [22] Tumor necrosis factor-α (TNF-α) is a master regulator of inflammatory responses that accelerate atherosclerosis. 23 TNF-α enhances murine hematopoietic stem and progenitor cell proliferation 24 and macrophage differentiation, 25 which may cause monocytosis and increase plaque burden. 26 Antiatherosclerotic effects of TNF-α blockade in patients with rheumatoid arthritis have been reported. 27, 28 However, these effects are not conclusive. 2 To investigate whether the protective role of TNF-α blockade in atherosclerosis is dependent on the cause of inflammation, we used a commercially available therapeutic antibody (adalimumab) and evaluated its effects on atherosclerosis in low-density lipoprotein receptor knock-out (LDLR) −/− mice reconstituted with bone marrow from either wild-type (WT) mice or from mice carrying macrophage deletion of LRP1 (MΦLRP1 −/− ), global deletion of apoE (apoE −/− ), or both (DKO). We show that adalimumab suppresses TNF-α levels and Ly6C hi monocytosis in all mice, but only reduces atherosclerotic burden in mice expressing macrophage LRP1. Mice without macrophage LRP1 showed defective efferocytosis and increased atherosclerosis burden, which were not improved by TNF-α blockade.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

TNF-α Antibody Reduces Atherosclerosis in WT→LDLR −/− , but Not in MΦ LRP1 −/− →LDLR −/− Mice
To investigate the antiatherosclerotic effects of TNF-α blockade in different inflammation models, 12-week-old female LDLR −/− mice received lethal irradiation and were reconstituted with bone marrow from WT or MΦLRP1 −/− mice. Four weeks after bone marrow transplant (BMT), recipient mice were treated with the TNF-α antibody adalimumab or human IgG (control) by intraperitoneal injection twice weekly for 10 weeks while on a Western-type diet. Mice receiving MΦLRP1 −/− bone marrow (MΦLRP1 −/− →LDLR −/− ) showed a 150% increase in atherosclerosis (P<0.001; Figure 1A and 1B) compared with WT bone marrow recipients (WT→LDLR −/− ). Plasma cholesterol levels were unchanged, but triglyceride levels were slightly increased in MΦLRP1 −/− →LDLR −/− mice ( Figure 1D and 1E ). TNF-α blockade suppressed aortic sinus area atherosclerosis by 52% in WT→LDLR −/− (193.9±31.6 versus 93.3±19.6×10 3 μm2; P<0.05), but did not significantly change lesion size (296.1±18.9 versus 319±30.2×10 3 μm 2 ) in MΦLRP1 −/− →LDLR −/− mice ( Figure 1A and 1B). Adalimumab suppressed plasma TNF-α levels in both groups of mice ( Figure 1C ), without affecting plasma cholesterol or triglyceride levels ( Figure 1D and 1E).
Nonstandard Abbreviations and Acronyms
TNF-α Antibody Suppresses Apoptotic Cell Accumulation and Reduces Necrosis in Atherosclerotic Lesions of WT→LDLR −/− , but
Not in Lesions of MΦLRP1 −/− →LDLR −/− mice Accumulation of apoptotic macrophages in the lesion has been shown to cause inflammatory responses and contribute to atherosclerosis progression. 8, 29 We previously reported that MΦLRP1 −/− increased lesion cellularity and apoptotic cells. 20 To evaluate whether this effect is dependent on TNF-α, we quantified the number of apoptotic cells in the plaque of adalimumab-treated and control BMT mice. The apoptotic cell burden increased by 130% in lesions of MΦLRP1 −/− →LDLR −/− mice compared with those of WT→LDLR −/− mice (P<0.05; Figures 2A and 2C ). Interestingly, adalimumab reduced apoptotic cells by 36% in WT→LDLR −/− mice, but did not have any effect in MΦLRP1 −/− →LDLR −/− mice (P<0.05; Figure 2A and 2C). Accumulation of apoptotic cells in the lesion contributes to necrosis. 1 We evaluated lesion necrosis by staining sections with hematoxylin-eosin as previously described 20 and found a 180% increase in necrosis in MΦLRP1 −/− →LDLR −/− mice compared with WT→LDLR −/− mice (P<0.001; Figure 2B and 2D). Adalimumab reduced necrosis in WT→LDLR −/− mice by 59% (P<0.001), but did not have any effect in MΦLRP1 −/− →LDLR −/− mice, consistent with the results we obtained for apoptotic cells in lesions ( Figure 2B and 2D).
Macrophage LRP1 in Plaques Causes Efficient Efferocytosis and Limits Inflammatory Response, and TNF-α Blockade Has No Effect on Efferocytosis in Lesions
Clearance of apoptotic cells limits postnecrotic inflammation and promotes inflammation resolution. The relative proportion of apoptotic cells internalized by macrophages is a measure of efferocytosis efficiency, 20, 22, [30] [31] [32] and an increase in the percentage of free apoptotic cells is an index of inefficient efforocytosis. The percentage of free apoptotic cells in lesions of MΦLR P1 −/− →LDLR −/− mice was 280% larger than that in lesions of WT→LDLR −/− mice (P<0.001; Figure 2A and 2E), suggesting impaired efferocytosis in the absence of macrophage LRP1. Adalimumab did not affect efferocytosis in either mouse type (Figure 2A and 2E). Efficient efferocytosis promotes production of anti-inflammatory cytokines and induces anti-inflammatory macrophage (M2) polarization. 11, 33 To evaluate the inflammatory response, we stained lesion macrophages for CD68 and used arginase-1 (Arg1) as anti-inflammatory (M2) marker and arginase-2 (Arg2) as proinflammatory (M1) marker. As shown in Figure 3 , total macrophage (CD68 + ) numbers increased by 130% (P<0.001) and M1 macrophages (Arg2 + , CD68 + ) increased TNF-α blockade suppressed the inflammation response in lesions and reduced lesion size in WT→LDLR −/− mice. Consistent with a previous report, 21 we show that the deletion of macrophage LRP1 increased lesion cellularity, caused defective efferocytosis, and increased atherosclerosis burden. These effects could not be improved by TNF-α blockade in the absence of LRP1.
Adalimumab Suppresses Atherosclerosis in apoE −/− →LDLR −/− Mice, but This Effect Is Reduced If Macrophage LRP1 Is Also Absent
ApoE deletion promotes systemic inflammatory responses. 5, 34 Adalimumab suppresses inflammation caused by hyperlipidemia in WT BMT mice. To test the antiatherosclerotic effects of TNF-α blockade in the absence of macrophage apoE −/− , we used LDLR −/− mice as recipients of bone marrow from mice lacking either apoE (apoE −/− →LDLR −/− ) or apoE and macrophage LRP1 (DKO→LDLR −/− ). As expected from our previous work, 35 apoE −/− →LDLR −/− mice showed a 160% increase in atherosclerotic burden compared with WT→LDLR −/− mice (301.1±19.22 versus 193.9±31.6×10 3 μm 2 ; P<0.001). The atherosclerotic burden was 140% greater in DKO→LDLR −/− mice than in apoE −/− →LDLR −/− mice (418.0±31.2 versus 301.1±19.22×10 3 μm 2 ; P<0.001; Figure 4 ). Adalimumab reduced atherosclerosis by 57% (P<0.001) in apoE −/− BMT mice, but only by 19% (P<0.05) in DKO→LDLR −/− mice ( Figure 4A and 4B) . Similar to what has been reported for WT→LDLR −/− and MΦLRP1 −/− →LDLR −/− mice, DKO→LDLR −/− mice had a slight increase in plasma triglyceride compared with apoE −/− →LDLR −/− mice ( Figure 4D and 4E). Adalimumab did not affect plasma cholesterol or triglyceride levels in either mouse group. Circulating TNF-α levels were increased by 200% (P<0.001) in apoE −/− →LDLR −/− compared with WT→LDLR −/− and did not further increase in DKO→LDLR −/− mice. Adalimumab suppressed TNF-α levels by 34% in apoE −/− →LDLR −/− mice and by 27% in DKO→LDLR −/− mice ( Figure 4C ).
Deficiency of Macrophage LRP1 Decreases Efferocytosis and Reduces the Ability of TNF-α Antibody to Suppress Apoptosis and Necrosis
Total apoptotic cells increased by 160% in DKO→LDLR −/− mice compared with apoE −/− →LDLR −/− mice (90.2±5.6 versus 
Adalimumab Reduces Macrophage Cellularity and Decreases Inflammatory Responses in the Lesion That Depends on Macrophage LRP1
Coincident with the increased lesion size, total macrophage (CD68 + ) numbers increased by 160% in apoE −/− →LDLR −/− compared with WT→LDLR −/− mice (624.1±36.4 versus 370.9±17.3 cells/mm 2 ; P<0.001), and a similar change affected M1 (arg2 + , CD68 + ) macrophages (154.1±6.9 versus 39.7±2.1 cells/mm 2 ; P<0.001). Total macrophages increased by 130% (P<0.01) and M1 macrophages increased by 170% (P<0.01; Figure 6 ) in DKO→LDLR −/− relative to apoE −/− →LDLR −/− mice. Adalimumab suppressed total macrophages and M1 macrophages in apoE −/− →LDLR −/− mice and was less effective in DKO→LDLR −/− mice ( Figure 6A through 6F) . Figure 6G ). The administration of adalimumab did not affect M2 macrophage abundance or percentage in the lesion ( Figure 6G ). These data indicate that deletion of apoE in bone marrow-derived cells or deletion of macrophage LRP1 reduces M2 polarization. Furthermore, TNF-α blockade with adalimumab does not affect M2 macrophage polarization.
Macrophage LRP1 Is Required for the Suppression of Ly6C Cells in the Lesion by Adalimumab
Blood ly6C hi monocytes give rise to inflammatory macrophages in the atherosclerotic plaque. 7 Ly6C expression is downregulated during monocytes' differentiation into macrophages in the lesion, but is still detectable within 48 hours of monocyte migration. 36 We evaluated ly6C hi monocytes in blood and ly6C-positive cells in lesions in all BMT mice. Blood ly6C hi monocytes were similar for WT→LDLR −/− and MΦLR P1 −/− →LDLR −/− mice ( Figure 7B ; Figure II in the online-only Data Supplement). Adalimumab reduced blood ly6C hi monocytes by 42% in WT→LDLR −/− mice (P<0.01) and by 34% in MΦLRP1 −/− →LDLR −/− mice (P<0.05; Figure 7B ). Blood ly6C hi monocytes increased by 250% in apoE −/− →LDLR −/− mice compared with WT→LDLR −/− mice (2.1±0.2 versus 0.8±0.1×10 4 /mL; P<0.001). Blood ly6C hi monocytes were not further increased in DKO→LDLR −/− mice ( Figure 7B ). Adalimumab significantly suppressed blood ly6C hi monocytes in apoE −/− → and DKO→LDLR −/− mice ( Figure 7B ). Lesion ly6C-positive cells increased by 130% in MΦLRP1 −/− →L DLR −/− compared with WT→LDLR −/− mice (P<0.001; Figure  7A and 7C). Adalimumab reduced lesion ly6C-positive cells by 54% in WT→LDLR −/− mice (139.8±11.9 versus 92.4±6.9 cells/mm 2 ; P<0.01), but did not alter lesion ly6C-positive cells in MΦLRP1 −/− →LDLR −/− mice (184.7±12.7 versus 157.6±7.7; n.s.; Figure 7A and 7C). Lesion ly6C-positive cells increased by 150% in apoE −/− →LDLR −/− compared with WT→LDLR −/− mice (210.3±9.3 versus 139.8±11.9 cells/ mm 2 ; P<0.01; Figure 7A and 7C). Lesion ly6C-positive cells were further increased by 130% in DKO→LDLR −/− mice compared with apoE −/− →LDLR −/− mice (P<0.001; Figure  7A and 7C). There was no significant difference in ly6C cells between MΦLRP1 −/− →LDLR −/− and apoE −/− →LDLR −/− mice ( Figure 7C ). Adalimumab reduced lesion ly6C cells by 35% in apoE −/− →LDLR −/− mice (P<0.01; Figure 7A and 7C) and was less effective for the reductions of ly6C cells in DKO→LDLR −/− mice (by 27%; P<0.05; Figure 7A and 7C).
Migration of inflammatory monocytes from blood to the lesion is driven both by monocytosis and by chemoattractant cytokines secreted by endothelial cells. To better understand the mechanisms by which adalimumab fails to suppress inflammation in the absence of LRP1, we evaluated endothelial expression of monocyte chemoattractant protein 1 (MCP-1) and vascular cell adhesion molecule 1 in the atherosclerotic lesion. Immunostaining density of MCP-1 in endothelial cells in lesions of MΦLRP1 −/− →LDLR −/− mice increased by 171% compared with WT→LDLR −/− mice (19.2±1.3 versus 11.2±1.2; P<0.05; Figure 7D and 7E). Adalimumab suppressed MCP-1 staining by 61% in lesions of WT→LDLR −/− mice but not in MΦLRP1 −/− →LDLR −/− mice ( Figure 7D and 7E ). Immunostaining density Figure 7D and 7E). Adalimumab suppressed MCP-1 staining by 44% in lesions of apoE −/− →LDLR −/− mice and by 21% in lesions of DKO→LDLR −/− mice ( Figure 7D and 7E ). There was no significant difference in MCP-1 expression between MΦLRP1 −/− →LDLR −/− mice and apoE −/− →LDLR −/− mice, suggesting that both macrophage LRP1 and apoE are important for limiting the recruitment of monocytes. In addition, expression of vascular cell adhesion molecule 1 in endothelial cells of the lesion had the similar pattern as the expression of MCP-1 for all groups of mice (unpublished data). Together, with results for atherosclerotic inflammation (Figures  3 and 6 ) and systemic inflammation ( Figure 7B ), these data show that (1) deletion of macrophage LRP1 increases both atherosclerotic plaque inflammation and MCP-1-mediated recruitment of ly6C hi monocytes in atherosclerotic lesions, (2) systemic inflammation caused by macrophage apoE deficiency increases ly6C hi monocyte migration into the lesion, plaque inflammation, and MCP-1 expression, and (3) adalimumab reduces blood ly6C hi monocytes, plaque MCP-1 expression, and plaque inflammation in WT BMT mice or mice lacking macrophage ApoE, but not in mice lacking macrophage LRP1 (Figure 8 ). Overall, these data indicate that loss of apoE and LRP1 in macrophages has synergistic effects to increase atherosclerosis burden and that adalimumab reduces atherosclerosis through a pathway that requires macrophage LRP1.
Discussion
We examined atherosclerotic burden in hyperlipidemic mice known to have defective efferocytosis (MΦLRP1 −/− → LDLR −/− ), increased inflammation (apoE −/− →LDLR −/− ), or both (DKO→LDLR −/− ). We also examined whether suppressing inflammation using adalimumab, a blocking TNF-α antibody, could reduce atherosclerotic burden in these models. Adalimumab suppressed cytokine production and blood ly6C hi monocytes in all recipients of BMT. In WT→LDLR −/− mice, the adalimumab-mediated reduction in blood proinflammatory ly6C hi monocytes was associated with reduced MCP-1 expression, reduced ly6C-positive cells in the lesion, and decreased atherosclerosis. MΦLRP1 −/− →LDLR −/− mice showed increased necrosis and apoptosis, as well as defective efferocytosis and increases in inflammation in the lesion, which could not be suppressed by adalimumab. Despite reduced blood ly6C hi monocytes, adalimumab failed to reduce MCP-1 expression and ly6C-positive cells in the lesion and failed to prevent atherosclerosis progression in MΦLRP1 −/− →LDLR −/− mice. Deletion of apoE in bone marrow-derived cells in apoE −/− →LDLR −/− mice promoted systemic inflammation and blood ly6C hi monocytosis. Adalimumab-mediated reduction in blood ly6C hi monocytes was associated with reduced MCP-1 expression and ly6C-positive cells in the lesion and reduced atherosclerosis. Similar to MΦLRP1 −/− →LDLR −/− mice, despite reduced blood ly6C hi , adalimumab was less effective in suppresssing atheroslecrosis in the absence of macrophage LRP1 in DKO→LDLR −/− mice.
We show that TNF-α blockade is effective in suppressing atherosclerosis caused by macrophage ApoE deletion, but not effective in suppressing atherosclerosis caused by macrophage LRP1 deletion. Loss of macrophage ApoE may cause atherosclerosis through increased systemic inflammation. Loss of macrophage LRP1, however, causes atherosclerosis via reduced macrophage efferocytosis. Although studies in mice have shown that genetic deletion of TNF-α reduces atherosclerosis, 37, 38 the antiatherosclerotic effects of monoclonal antibody-mediated blocking of systemic TNF-α have not been conclusively demonstrated. In humans, protective effects of adalimumab for cardiovascular disease have been reported in patients with rheumatoid arthritis or psoriasis. 27, 28 Adalimumab reduced vascular inflammation and improved endothelial function in these patients, reducing carotid atherosclerosis and arterial stiffness. 27, 28 However, another study has not been able to detect a significant effect of TNF-α inhibitors on the risk of cardiovascular events. 2 Our data indicate that adalimumab therapy may be effective in reducing risk of atherosclerosis in cases of increased systemic inflammation involving a pathway requiring macrophage LRP1 expression.
Ly6C hi monocytosis is an important contributor to atherosclerosis by fueling lesion cellularity. 39, 40 Migration of inflammatory monocytes to the lesion is determined by the secretion of chemoattractant cytokines, such as MCP-1, and by the expression of adhesion molecules, such as vascular cell adhesion molecule 1, by endothelial cells on the artery wall. 41 We demonstrate that TNF-α blockade suppressed blood ly6C hi monocytes and prevents atherosclerosis in an LRP1-dependent pathway. In the absence of LRP1, increased plaque inflammation enhances the MCP-1 expression and increases recruitment of ly6C hi monocytes to the atherosclerotic lesion. TNF-α blockade, despite the suppression of systemic ly6C monocytes, did not reduce monocyte recruitment in the absence of macrophage LRP1. These results support a scenario where the increased inflammation afforded by MΦLRP1 −/− promotes overexpression of MCP-1 and vascular cell adhesion molecule 1 by adjacent endothelial cells, which further promotes monocyte/macrophage infiltration and local inflammation and could not be suppressed by adalimumab.
After migration into the atheroma, ly6C hi monocytes preferentially differentiate into the proinflammatory M1 phenotype, downregulating ly6C expression and upregulating CD68 expression. 36 Our results showing a decrease in ly6Cpositive cells in the lesion suggest a suppression of the migration of ly6C hi cells to the arterial wall. Furthermore, in vitro 3 H-thymidine-labeling experiments showed no differences in uptake between macrophages of WT, MΦLRP1, apoE −/− , and DKO genotypes (not shown), indicating that the decrease found in total and M1 macrophages in lesions of adalimumabtreated mice was not because of altered proliferation. Systemic inflammation was elicited by Western diet in WT→LDLR −/− mice and was further stimulated in apoE −/− →LDLR −/− mice ( Figures 1C and 4C) . Consistent with the study reported by Murphy et al, 42 absence of macrophage apoE increased blood ly6C hi monocytes in apoE −/− →LDLR −/− and DKO −/− →LDLR −/− mice (Figure 7 ) because of the elevated proliferation of hematopoietic stem and progenitor cell under Western-type diet. Increases in blood ly6C hi drove the monocyte migration to the atherosclerotic lesion. Hematopoietic stem and progenitor cell proliferation was not changed by macrophage LRP1 deletion in vivo, likely because LRP1 was not expressed in bone marrow cells ( Figure III in the online-only Data Supplement).
Macrophage apoptosis is a fundamental process in the development of the atherosclerotic plaque. 29 Oxidative stress, abnormal secretion of proinflammatory cytokines, and endoplasmic reticulum stress are among the most common inducers of apoptotic cell death. [43] [44] [45] We showed that adalimumab was effective in reducing apoptotic cell content only in WT→LDLR −/− mice but not in MΦLRP1 −/− →LDLR −/− mice. Similarly, adalimumab reduced apoptosis in the absence of apoE in bone Western diet, alone or together with apoE deletion, increases circulating inflammatory monocytes. Efferocytosis causes apoptotic cell removal, limits M1 and promotes M2 macrophage polarization, reduces postapoptotic necrosis, and improves the resolution of inflammation. Both paths influence the ability of ly6C hi monocytes to infiltrate the intima and modulate atherogenesis. TNFα-blocking antibodies suppress blood monocytosis, migration of proinflammatory monocytes, lesion cellularity, and atherosclerosis, but do not affect efferocytosis. Loss of macrophage LRP1 drastically impairs efferocytosis, thus promoting inflammatory responses, stimulating endothelium chemoattractant cytokine expression, and increasing proinflammatory monocyte migration and atherosclerosis. These effects are not responsive to the antiatherosclerotic action of TNF-α blockade. marrow-derived cells, but was less effective when macrophage LRP1 was also absent. In early lesions, efficiency of apoptotic cell clearance is associated with a decrease in lesion cellularity and reduction of atherosclerosis progression. However, in advanced lesions, the progressive inefficiency of apoptotic cell clearance by phagocytes leads to increases in necrosis, with consequent increase in plaque inflammation and enlargement of the necrotic core. 46 Similar to apoptosis, we demonstrated that adalimumab significantly reduced necrosis, but only in the presence of MΦLRP1. When apoE was absent, adalimumab improved necrosis, but was less effective when both macrophage apoE and LRP1 were deficient. This indicates that the effects of TNF-α blockade on apoptosis and necrosis depend on LRP1.
Macrophage LRP1 acts as a recognition receptor for apoptotic cell removal, 13, [15] [16] [17] and defective efferocytosis in hyperlipidemic mice with macrophage LRP1 deletion has been reported. [18] [19] [20] In this study, the percentage of free apoptotic cells in lesions was higher in BMT mice carrying macrophages without LRP1, showing defective efferocytosis in those mice (Figures 2 and 5 ). Apoptosis at a single-cell level was quantified using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) technology. Free apoptotic cells were defined as TUNEL-positive bodies not colocalized with CD68, a method we and others used previously. 20, 22, [30] [31] [32] A limitation of this method is that TUNEL-positive bodies are also found within cells that do not stain positive for CD68, thus providing evidence that other phagocytes also take up apoptotic cells. However, as shown in Figures 3 and 6 , >90% of cells in lesion were CD68 positive. In addition, our previous work showed that lymphocytes and dendritic cells do not express LRP1 in mouse. 47 Thus, we estimate that the contribution of other cell types such as dendritic cells would be minimal. Of interest, Eriksson et al 48 reported an increase in LRP1 (CD91) expression in CD3-expressing T lymphocytes in patients who did not respond to anti-TNF-α antibody treatment. Although the mechanism was not clear, the authors proposed that the increased CD91 expression was caused by the overstimulation of T cells. 48 Defective efferocytosis is closely associated with inflammation. 8, 11 However, despite the effect of adalimumab on inflammation, it did not affect efferocytosis in any of the treated groups in our study.
Our results show that anti-TNF-α therapy inhibits atherosclerosis induced by Western-type diet or macrophage apoE deletion in hyperlipidemic mice. The effect is because of improved local inflammatory response, with fewer ly6C hi monocytes in the circulation and reduced monocyte recruitment into the atheroma. Despite the reduction of systemic levels of TNF-α and ly6C hi monocytes, adalimumab was ineffective in inhibiting the local inflammatory response in the absence of LRP1, indicating that macrophage LRP1 is necessary for the anti-inflammatory effect of TNF-α blockade.
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• Atherosclerosis is an inflammatory process but anti-inflammatory drugs have not proven to reduce cardiovascular disease rates. • Vascular inflammation in atherosclerosis has the unique component of lipid-laden cells undergoing apoptosis and necrosis. • It is not clear whether cell death and removal of cellular debris (efferocytosis) contribute to vascular inflammation. • Monoclonal antibody that reduces inflammation via tumor necrosis factor-α blockade also reduces atherosclerosis in a murine model but only if the receptor low-density lipoprotein receptor-related protein 1 is present on the macrophage. • Absence of low-density lipoprotein receptor-related protein 1 results in defective efferocytosis and persistent inflammation, thus suggesting that local cell survival and recruitment of circulatory inflammatory cells are driving factors of inflammation in the atheroma.
